Bictegravir-Tenofovir alafenamide-Emtricitabine Biktarvy
Darunavir-Cobicistat-Tenofovir alafenamide-Emtricitabine Symtuza
Dolutegravir-Abacavir-Lamivudine Triumeq
Dolutegravir-Lamivudine Dovato
Dolutegravir-Rilpivirine Juluca
Doravirine-Tenofovir DF-Lamivudine Delstrigo
Efavirenz-Tenofovir DF-Emtricitabine Atripla
Elvitegravir-Cobicistat-Tenofovir alafenamide-Emtricitabine Genvoya
Elvitegravir-Cobicistat-Tenofovir DF-Emtricitabine Stribild
Rilpivirine-Tenofovir alafenamide-Emtricitabine Odefsey
Rilpivirine-Tenofovir DF-Emtricitabine Complera
Enfuvirtide Fuzeon
Fostemsavir Rukobia
Ibalizumab Trogarzo
Maraviroc Selzentry
Dolutegravir Tivicay
Raltegravir Isentress
Abacavir Ziagen
Abacavir-Lamivudine Epzicom
Abacavir-Lamivudine-Zidovudine Trizivir
Didanosine Videx
Emtricitabine Emtriva
Lamivudine Epivir
Stavudine Zerit
Tenofovir alafenamide-Emtricitabine Descovy
Tenofovir DF Viread
Tenofovir DF-Emtricitabine Truvada and Multiple Generics
Zidovudine Retrovir
Zidovudine-Lamivudine Combivir
Doravirine Pifeltro
Efavirenz Sustiva
Etravirine Intelence
Nevirapine Viramune
Rilpivirine Edurant
Atazanavir Reyataz
Atazanavir-Cobicistat Evotaz
Darunavir Prezista
Darunavir-Cobicistat Prezcobix
Fosamprenavir Lexiva
Indinavir Crixivan
Lopinavir-Ritonavir Kaletra
Nelfinavir Viracept
Saquinavir Invirase
Tipranavir Aptivus
Cobicistat Tybost
Ritonavir NorvirHIV in Older Adults
10 questions
Learning Objectives
- Recognize age-related and HIV-related changes to the immune systems of people 50 years of age and older
- Summarize cognitive and functional changes that may interfere with adherence to care in people with HIV who are 50 years of age and older
- List recommendations for antiretroviral therapy management in persons 50 years of age and older.
- Explain expected virologic and immunologic responses to antiretroviral therapy in persons 50 years of age and older.
- Discuss common comorbidities of people with HIV who are 50 years of age and older
Authors
David H. Spach, MD
David H. Spach, MD
Professor of Medicine
Division of Allergy & Infectious Diseases
University of Washington
Professor of Medicine
Division of Allergy & Infectious Diseases
University of Washington
Disclosures: None
Reviewers
Jehan Z. Budak, MD
Jehan Z. Budak, MD
Assistant Professor of Medicine
Division of Allergy & Infectious Diseases
University of Washington
Assistant Professor of Medicine
Division of Allergy & Infectious Diseases
University of Washington
3rd Edition
This is a substantial revision of the original Question Bank Topic. The previous edition was titled HIV in Older Adults and available until September 1st, 2023.
CNE/CME Continuing Education
This question bank topic qualifies for:
View CE Notices
- 1 CME AMA PRA Category 1 Credit™, or
- 1 CNE contact hour (qualifies for pharmacology CE for advanced practice nurses)
CNE and CME Origination: September 17th, 2018
CNE and CME Reviewed: July 27th, 2020
CNE and CME Reviewed: September 1st, 2023
CNE and CME Expiration: August 31st, 2026 (3rd Edition)
View CE Notices
Steps to Acquire CE for this Question Bank Topic:
1
Answer
Answer all questions
2
Score 80%+
Answer correctly
3
Claim CE
Choose CNE or CME
4
Give Feedback
Complete survey
5
Print Certificate
Obtain proof of CE Explore this topic in detail in the HIV in Older Adults Quick Reference,
or earn more CE for it in the HIV in Older Adults Self-Study
or earn more CE for it in the HIV in Older Adults Self-Study